| Bioactivity | FABP-IN-1 (Compounds 4b) is a high affinity fatty acid binding protein (FABP) inhibitor. FABP-IN-1 inhibits FABP3, FABP5, and FABP7 with Ki values of 0.69 μM, 0.55 μM and 0.67 μM, respectively. FABP-IN-1 displays potent antinociceptive effects[1]. | |||||||||
| Target | Ki: 0.69 μM (FABP3), 0.55 μM (FABP5) and 0.67 μM (FABP7) | |||||||||
| In Vivo | FABP-IN-1 (Compounds 4b; 20 mg/kg; intraperitoneal injection; for 90 minutes; male wild-type C57BL/6 mice) treatment displays potent antinociceptive effects in CFA model[1]. Animal Model: | |||||||||
| Name | FABP-IN-1 | |||||||||
| CAS | 2132990-90-8 | |||||||||
| Formula | C30H26O6 | |||||||||
| Molar Mass | 482.52 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Yan S, et al. SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins. Eur J Med Chem. 2018 Jun 25;154:233-252. |